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Abstract
Background: Granulocyte colony stimulating factor (GCSF) is protective in animal models of various
neurodegenerative diseases. We investigated whether pegfilgrastim, GCSF with sustained action, is protective in a
mouse model of amyotrophic lateral sclerosis (ALS). ALS is a fatal neurodegenerative disease with manifestations of
upper and lower motoneuron death and muscle atrophy accompanied by inflammation in the CNS and periphery.
Methods: Human mutant G93A superoxide dismutase (SOD1) ALS mice were treated with pegfilgrastim starting at
the presymptomatic stage and continued until the end stage. After long-term pegfilgrastim treatment, the
inflammation status was defined in the spinal cord and peripheral tissues including hematopoietic organs and
muscle. The effect of GCSF on spinal cord neuron survival and microglia, bone marrow and spleen monocyte
activation was assessed in vitro.
Results: Long-term pegfilgrastim treatment prolonged mutant SOD1 mice survival and attenuated both astro- and
microgliosis in the spinal cord. Pegfilgrastim in SOD1 mice modulated the inflammatory cell populations in the
bone marrow and spleen and reduced the production of pro-inflammatory cytokine in monocytes and microglia.
The mobilization of hematopoietic stem cells into the circulation was restored back to basal level after long-term
pegfilgrastim treatment in SOD1 mice while the storage of Ly6C expressing monocytes in the bone marrow and
spleen remained elevated. After pegfilgrastim treatment, an increased proportion of these cells in the degenerative
muscle was detected at the end stage of ALS.
Conclusions: GCSF attenuated inflammation in the CNS and the periphery in a mouse model of ALS and thereby
delayed the progression of the disease. This mechanism of action targeting inflammation provides a new
perspective of the usage of GCSF in the treatment of ALS.
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Background
ALS is a neurodegenerative disorder leading to progres-
s i v eu p p e ra n dl o w e rm o t o n e u r o nd e c l i n e ,m u s c l ea t r o -
phy and death within a few years from diagnosis [1].
The majority of ALS cases are sporadic while up to 10%
are familial. One of the mutations causing familial ALS
occurs in the copper/zinc (Cu/Zn) superoxide dismutase
1( S O D 1 )g e n ea sf i r s td e s c r i b e db yR o s e net al.[ 2 ] .
SOD1 is a homodimeric metalloenzyme which catalyzes
t h ec o n v e r s i o no fat o x i cs u p e r o x i d ea n i o nO 2
- to oxy-
gen and hydrogen peroxide. The toxicity mechanisms of
mutant SOD1 are not completely understood but
mutant SOD1 is thought to cause the disease by a toxic
gain of function which is linked to mutant SOD1 aggre-
gation and oxidative stress [3]. Since the clinical and
pathological nature of familial and sporadic ALS are
similar, mechanisms of mutant SOD1 toxicity are
thought to elucidate the disease mechanisms also in
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mutant SOD1 have been widely used to study ALS
pathogenesis [3].
ALS or SOD1-mediated pathology is accompanied by
multiple cellular and subcellular abnormalities including
deficits in the axonal transport and mitochondrial func-
tions [3]. Abnormal SOD1 activity has also been shown
to impair neuromuscular function [4,5]. Although the
motoneuron degeneration is a hallmark of ALS [1] the
disease may actually initiate from the periphery. Deficits
in neuromuscular function may precede motoneuron
deficits [6] and even the muscle-restricted expression of
mutant SOD1 may be sufficient to initiate the ALS
pathology with subsequent motoneuron degeneration
[7]. Non-neuronal cells, namely microglia and astrocytes,
participate in CNS homeostasis by secreting trophic
molecules and helping to maintain proper neuronal sig-
naling. On the other hand, they may also secrete mole-
cules that disrupt the CNS homeostasis. Microglia and
astrocytes thus play a crucial role in ALS pathology [8]
by regulating neuroinflammation. Also, the microglia
turnover by myeloid cells from the circulation may play
a role in neurodegenerative diseases as previously
reviewed [9]. In addition, peripherally derived myeloid
cells may infiltrate not only into the CNS [10-13] but
also migrate into the peripheral nervous system (PNS)
or skeletal muscle [10,14] and potentially participate in
ALS progression. Myeloid cells exist in different pheno-
types, so-called pro-inflammatory and anti-inflammatory
forms, also known as classical and alternatively activated
monocytes, which may contribute to inflammation and
tissue regeneration in a different manner [15]. The treat-
ment modulating these monocyte subsets and thus
inflammation may provide a potential therapy for neuro-
degenerative diseases.
GCSF is a hematopoietic growth factor which is cur-
rently in clinical use to mobilize stem cells into the cir-
culation prior to apheresis [16] and to treat neutropenia
after cytostatic therapy. GCSF has a wide variety of
actions; it reduces apoptosis, drives neurogenesis and
angiogenesis and attenuates inflammation [17-22]. GCSF
is protective in myocardial infarction in animal models
and it has also been tested for clinical use after acute
and chronic ischemic heart diseases as reviewed by
Kastrup et al. [23]. Moreover, GCSF has been shown to
be protective in animal models of acute and chronic
neurodegenerative diseases as reviewed in Diederich et
al. [24], including stroke, Alzheimer’s disease, Parkin-
son’sd i s e a s ea n ds p i n a lc o r di n j u r y[ 2 5 - 2 7 ] .G C S Fw a s
recently shown to be protective also in animal models
of ALS [28], mediating its protective effects via P13/Akt
pathway, an antiapoptotic transduction pathway down-
stream of GCSF signaling in neurons [17]. GCSF was
also shown to be neuroprotective after peripheral axot-
omy [29,30].
GCSF is conventionally administered as repeated daily
injections of filgrastim. Pegfilgrastim, a pegylated filgras-
tim, shows sustained activity in vivo because of its
reduced renal clearance [31] which enables longer inter-
vals for its application compared to filgrastim [32,33].
Peripherally administered GCSF is taken into the CNS
most probably by a receptor-mediated transport [34]. In
the CNS, GCSF receptors are expressed in neurons and
microglia [17,28] but not astrocytes [17]. GCSF receptor
is also expressed in peripheral monocytes and granulo-
cytes [21,35]. In humans, GCSF administration increases
the production of hematopoietic stem cells, granulocytes
and monocytes [21]. GCSF therapy has been in phase I
clinical trials for ALS where it has been proven to be a
safe treatment for ALS [36-39]. However, the mechan-
ism of action of GCSF is not fully known in ALS.
T h i ss t u d yp r o v i d e sd a t af o rt h eu s a g eo fG C S Fw i t h
sustained action in a mouse model of ALS. The long-
term treatment with pegfilgrastim prolonged the survival
of mutant SOD1 mice and attenuated both astro- and
microgliosis in the spinal cord. Pegfilgrastim also modu-
lated the inflammatory cell populations in the bone
marrow (BM) and spleen in mutant SOD1 mice and
reduced the production of pro-inflammatory cytokine
TNFa. GCSF also reduced the inflammatory activation
of microglia in vitro. After long-term pegfilgrastim treat-
ment, the increased storage of Ly6C cells in the BM and
spleen was accompanied by increased migration of
monocytes, or their survival in the degenerative muscle
at the symptomatic stage of ALS. This suggests that
GCSF therapy delays the progression of ALS in a trans-
genic mouse model through the attenuation of inflam-
mation in both the CNS and the periphery.
Methods
Animals
SOD1 G93A (B6. Cg-Tg-(SOD1-G93A)1Gur/J) trans-
genic mice carrying a high copy number of human
mutant G93A SOD1 were obtained from Jackson
Laboratory and maintained on C57BL/6J congenic back-
ground. SOD1 G93A mice manifest motor deficits
between 17-19 weeks of age. Paralysis and end stage of
the disease are reached by age of 24-26 weeks. Male
SOD1 mice were used for survival and histological stu-
dies. Disease onset was determined by the wire-hang
test. Each mouse was suspended while hanging from a
wire cage top and latency was recorded. Deficits in
motor performance were defined by the inability to
hang for more than 3 minutes. The test was repeated 1-
2 times per week until the mouse was sacrificed. For
survival studies, the clinical end stage was defined as the
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onds which was regarded as a criterion for mouse sacri-
fice. Animal experiments were conducted according to
the national regulations of the usage and welfare of
laboratory animals and approved by the Animal Experi-
ment Committee in the State Provincial Office of South-
ern Finland.
Pegfilgrastim treatment
A single injection of pegfilgrastim has been determined
to equal to multiple injections of filgrastim in order to
mobilize stem cells or treat neutropenia. We treated the
mice with a submaximal dosage of pegfilgrastim as esti-
mated from previous studies performed with wt mice
[32,33]. Mice were treated with pegfilgrastim (Neulasta,
Amgen) at the dosage of 300 μg/kg given subcuta-
neously once per week. Pegfilgrastim was diluted into
0.15 M sodium acetate (pH 7.4, adjusted with acetic
acid) right before use. Sodium acetate injections were
used as a vehicle control. The treatment was started at
the age of 12 weeks for survival studies or at 12-16
weeks for histological studies. The treatment was con-
tinued once a week until the mouse was sacrificed. The
littermates were randomly and equally divided into
treatment groups. For histological studies, the pegfilgras-
tim-treated mice were sacrificed at the same age as
when their littermates reached the clinical end stage.
Immunohistochemistry
T h em i c ew e r ea n e s t h e t i z e dw i t ha no v e r d o s eo ft r i b r o -
moethanol (Avertin, Sigma) and transcardially perfused
with heparinized saline to remove blood from tissues.
The meninges were removed from spinal cord which
was then cut in half at the mid lumbar area and pre-
pared as paraffin-embedded sections and cut with a
microtome into 5 μm sections. The spinal cord sections
were immunostained with microtubule associated pro-
tein 2 (Map2, Boehringer Mannheim), neuronal nuclear
antigen (NeuN, Chemicon), choline acetyltransferase
(ChAT, Chemicon), glial fibrillary acidic protein (GFAP,
Chemicon) and ionized calcium binding adaptor mole-
cule-1 (Iba-1, Wako), followed by the detection with a
fluorescent or diaminobenzidine-based method as
described [40]. The immunoreactive area was quantified
from the ventral horn of the spinal cord. The total of 2
mm area of the mid lumbar spinal cord in each mouse
was covered, analyzed as 20 sections 100 μm apart.
Blood sample analysis
The blood sample was taken from the saphenous vein or
from the heart at the time of sacrifice. Repeated blood
sampling was avoided to keep the manipulation of
hematopoietic system minimal. The blood sample was
mixed with heparin and centrifuged to separate the
blood cells. The plasma was collected and stored at -70°
C until use. The GCSF concentration in blood was ana-
lyzed from plasma samples with a human GCSF ELISA
kit (R&D Systems) according to manufacturer’s protocol.
The flow cytometry staining of blood cells was per-
formed as described [40]. Briefly, nonspecific antigen
binding was blocked with mouse IgG (clone MOPC-21,
Sigma) and the cells were stained with fluorochrome-
conjugated PE-CD117 (Stem Cell Technologies), PerCP-
Gr-1 (BD Biosciences (BD)) and FITC-CD45 (BD), and
analyzed on a FACS Calibur (BD) equipped with a single
488 nm argon laser. The data are shown as percentage
of CD117 or Gr-1 cells of total CD45 blood leukocytes.
Cell isolation and cell culture
Spinal cord neurons were obtained from E14 mouse
embryos with a protocol modified from Vartiainen et al.
[41]. Briefly, embryos were decapitated and the spinal
cords were isolated. The meninges and the dorsal root
ganglia were removed. Spinal cords were digested in 0.5
mg/ml papain (Sigma), 0.04 mg/ml DNAse in PBS 5-10
min at 37°C. Papain solution was replaced with 1 mg/ml
BSA, 0.04 mg/ml DNAse, 10 mM glucose in PBS and
gently triturated and centrifuged. The pellet was resus-
pended into DMEM, 10% FBS, 2 mM glutamine, penicil-
lin-streptomycin (Gibco) and plated at 2.25 × 10
5 cells/
cm
2 onto poly-D-ornithine-coated (Sigma) multiwell
plates. The next day the medium was replaced with
Neurobasal, L-glutamine, penicillin-streptomycin supple-
mented with B27 (all from Gibco), 25 μMg l u t a m i ca c i d
(Sigma) and 10 μM AraC. After 24h, the medium was
replaced with Neurobasal with supplements excluding
AraC. One third of the medium was changed every
three days and the cells were used for experiments after
9 days in culture. When preparing cultures from SOD1
mice, the spinal cord of each embryo was processed
separately.
Mouse neonatal microglia cultures were prepared as
described earlier [42,43]. BM cells were collected as
described [40]. When needed, BM monocytes were
obtained with the mouse monocyte negative enrichment
kit (EasySep, Stem Cell Technologies) according to man-
ufacturer’s protocol. In splenocyte isolation, the spleen
was first injected with HBSS, 2% FBS to balloon the
spleen and the splenocytes were harvested by scraping
the spleen gently with a needle to release the cells from
the tissue. The cells were filtered through a 100 μm
nylon mesh (BD) and centrifuged. The erythrocytes
were lyzed with ammonium chloride as described [40].
Mononuclear cells were collected from thigh muscle
and sciatic nerve with Percoll method as modified from
Chiu et al. [14]. The tissue was minced with a scalpel
and digested for 1 h at 37°C in 2.5 mg/ml collagenase D
(Roche), 1 mg/ml DNAse (Roche) in HBSS (without
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the isolation, samples were periodically vortexed gently.
The homogenates were filtered through a 100 μmn y l o n
mesh (BD) and centrifuged. The pellet was resuspended
into isotonic 37% Percoll (Amersham) pH 7.4, in HBSS,
10 mM HEPES and carefully layered on top of 70% Per-
coll layer and centrifuged 500 g for 20 min at RT with
no brake. Mononuclear cells were collected from the
layer interphase.
When needed, the monocytes/mononuclear cells were
cultivated in IMDM, 10% FBS, 2 mM L-glutamine and
penicillin-streptomycin (reagents from Gibco, Invitro-
gen) in humidified atmosphere at 5% CO2 in 37°C. To
enhance monocyte survival, the cells were incubated in
the presence of 10 ng/ml MCSF (R&D Systems).
Recombinant human GCSF (Peprotech) was used in cell
culture studies instead of pegfilgrastim.
Cell staining and flow cytometry
The staining of cells was performed as described [40].
Nonspecific staining was blocked with mouse IgG
(MOPC-21, Sigma). Cells were stained with fluoro-
chrome-conjugated FITC-CD3, FITC-CD45R, FITC-
CD45, PE-CD11b, FITC-Ly6C, PerCP-Cy5.5-Ly6G (all
from BD), PE-CD115 (Serotec), or CCR2 (Lifespan
Technologies) followed by Alexa Fluor 488 (Molecular
Probes). A minimum of 10 000 events were acquired on
a FACSCalibur flow cytometer equipped with a 488 nm
argon laser (BD) and data analysis was performed using
Cellquest Pro software (BD).
Quantitative real-time PCR
Spinal cords were homogenized for RNA isolation. The
relative expression levels of specific inflammatory med-
iators tumor necrosis factor a (TNFa), inducible nitric
oxide synthase (iNOS), nuclear factor erythroid 2-related
factor 2 (Nrf2) target genes heme oxygenase 1 (HO1)
and NADPH quinone oxidoreductase 1 (NQO1) were
determined with quantitative RT-PCR as described [44].
The expression levels were normalized to ribosomal
RNA and represented as fold change in the expression
level of wt mice.
Cytokine assay
Cells were treated with 10 ng/ml LPS for 24 h. Medium
samples were collected and cytokine concentration
determined with TNFa ELISA (R&D Systems). Detec-
tion of intracellular cytokine production was performed
as described [45]. Briefly, cells were treated with 1 μg/
ml LPS for 6 h including Brefeldin A (Sigma) for the
last 4 h of incubation to inhibit protein transport and
enhance the detection of intracellular cytokines. Cells
were collected and stained for cell surface markers
(Ly6C or CD11b) as described above. Cells were fixed
with 4% paraformaldehyde for 20 min at RT then per-
meabilized with 0.05% saponin (Sigma). PE-conjugated
TNFa, IL-6 or IL-10 cytokine antibody or an isotype
control (all from eBioscience) was applied in PBS, 2%
FBS, 0.05% saponin and incubated 30 min at RT. Cells
were analyzed on a flow cytometer as described above.
Nitric oxide assay
Cells were treated with 10 ng/ml LPS for 24 h in a phe-
nol red-free medium. Medium samples were mixed with
an equal volume of Griess reagent (2% phosphoric acid,
1% sulfanilamide, 0.1% naphthylethylene dihydrochlor-
ide, Sigma), incubated for 10 min and absorbance mea-
sured at 540 nm with a multiscan reader. Sodium nitrite
(Sigma) was used as a standard.
Cell viability assay
Cells were incubated in culture medium with 10 μM
resazurin (Sigma) and incubated for 2 h (neurons) or 4h
(monocytes). Medium samples were collected into a 96-
well plate and measured by excitation at 544 nm and
emission at 590 nm on a multiplate reader (Victor
Wallac).
Western blot
PAkt was analyzed from cell culture samples with wes-
tern blotting as described [46].
Statistical analysis
The data are expressed as mean ± SD. The data were
analyzed with SPSS software using Kaplan-Meier survi-
val statistics with a log rank sum test for testing differ-
ences in mouse survival, and using general linear model
for testing differences in the motor performance test.
Other data were analyzed with Student’s T-test, Mann-
Whitney U-test or one-way Analysis of variance
(ANOVA) when appropriate, followed by Dunnett’so r
Tukey’s post hoc test. * (p <0.05), ** (p <0.01), *** (p
<0.001).
Results
GCSF with sustained activity prolongs the survival of
SOD1 mice
We first determined the plasma concentrations of GCSF
in mutant SOD1 mice after administration of pegfilgras-
tim. After an injection of pegfilgrastim, the plasma con-
centration of GCSF remained elevated for several days
(1A). However, the plasma concentration of GCSF low-
ered to basal level before the next dosage, given at one
week intervals. The data is shown after long-term
administration of pegfilgrastim (1A, black squares), indi-
cating that a prolonged application of a growth factor
peptide was not hampered by a formation of neutraliz-
ing antibodies, a possible risk linked to cytokine or
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by the fact that the first dosage of pegfilgrastim (1A,
open squares), analyzed at days 1 and 4, displayed simi-
lar GCSF rise and decay in plasma as observed after the
prolonged pegfilgrastim therapy. The classic effect of
GCSF was detected by increased neutrophil and stem
cell counts in the peripheral blood (1B and 1C, p <0.01)
after the first dose of GCSF. However, the leukocytosis
was restored back to the basal level after prolonged peg-
filgrastim treatment. Despite sustained plasma levels of
GCSF after long-term therapy, the excess mobilization
of leukocytes into the circulation was most likely hin-
dered due to a compensatory mechanism.
Prolonged pegfilgrastim therapy increased the survival
of SOD1 mice (1D, p <0.01). When compared to their
vehicle-controlled littermates, pegfilgrastim increased
the life expectancy from 173 ± 6.7 days to 185 ± 6.7
days with the range of 3-23 days. The time of onset did
n o td i f f e rb e t w e e nt h eg r o u p s( 1 E )a n dt h et i m ef r o m
the onset to death was thus prolonged with the pegfil-
grastim treatment (1F, p <0.05). The increased survival
time was accompanied by improved performance in a
Figure 1 GCSF with sustained activity has biological efficacy and prolongs the survival of mutant SOD1 mice. Mutant SOD1 mice were
treated with pegfilgrastim once a week starting at the age of 12 weeks. Plasma concentration of GCSF remained elevated multiple days after a
single injection of 300 μg/kg (A) but returned back to baseline at day 7 before the next dosage (data was obtained from 33 mice, 1-2 blood
samples/mouse). This occurred in a similar manner after the first dosage (A, open squares) as well as after the long-term pegfilgrastim treatment
(A, black squares). Pegfilgrastim elevated the levels of stem cells (B, p <0.01, n = 11) and granulocytes (C, p <0.01, n = 11) after the first dosage,
as analyzed four days after the pegfilgrastim administration, but the mobilization was decreased after prolonged pegfilgrastim treatment (n = 5).
Long-term pegfilgrastim treatment increased the survival of mutant SOD1 mice as shown with a Kaplan-Meier survival graph (D, p <0.01, n = 8-
9). Pegfilgrastim treatment did not delay the onset of the disease as determined by wire-hang test (E, n = 6) but increased the time from the
onset to death (F, p <0.05, n = 4-5). The prolonged survival was accompanied with improved motoric performance in wire-hang test (G, p <0.05,
n = 6) when analyzed within 5 weeks after the onset. The first mice died 5 weeks after the onset.
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sustained motoric capacity in GCSF-treated mutant
SOD1 mice compared to vehicle-treated littermates.
GCSF conducts neuroprotection in vitro
In order to uncover cellular and molecular mechanisms
of GCSF-mediated neuroprotection we tested the action
of GCSF on primary neuronal culture. Spinal cord neu-
ron culture consisted of NeuN positive neurons and to a
lesser extent, SMI-32 positive motoneurons, and the lat-
ter defined by the large size of the cell body and the
long axon typical to motoneurons [51] in spinal cord
cultures (2A and 2B). On non-stimulated neuronal cul-
tures, the treatment with GCSF increased the Akt phos-
phorylation (2C, p <0.05) as shown earlier in NSC34
secondary cells [28]. When spinal cord neurons were
exposed to glutamate-induced excitotoxicity in vitro,
GCSF reduced neuronal cell death (2D, p <0.001). GCSF
did not have any effect on neuron survival in control
conditions (2D). When spinal cord neuron culture was
prepared from mutant SOD1 mice we discovered that
the general cell viability was slightly reduced in mutant
SOD1 neurons and GCSF could alleviate the compro-
mised cell viability (2E, p <0.05). However, unlike wt
cells, GCSF did not protect mutant SOD1 neurons from
glutamate neurotoxicity (data not shown).
Next, to determine the effect of long-term pegfilgras-
tim treatment in vivo, spinal cord sections were analyzed
by immunohistochemistry. The neurodegeneration was
evident in mutant SOD1 mice when compared to wt
mice, as evaluated by reduced immunoreactivity for neu-
ronal markers (3A and 3B), Even though GCSF had cer-
tain neuroprotective properties in vitro,l o n g - t e r m
pegfilgrastim treatment did not significantly increase
spinal cord neuron survival in mutant SOD1 mice in
vivo (3A and 3B).
GCSF with sustained activity attenuates inflammation in
vivo
When the inflammation status was analyzed from the
spinal cords of the same mice, long-term pegfilgrastim
treatment indeed decreased astrogliosis and microgliosis
in the ventral horn of the spinal cord as determined
with GFAP (p <0.05) and Iba-1 (p <0.01) immunostain-
ing, respectively (3A and 3B). We further examined
whether reduction of inflammation in the spinal cord
could be detected in the level of inflammatory media-
tors. Firstly, quantitative PCR results showed that the
expression of TNFa was upregulated (34 ± 21 fold of
wt, p <0.01) and that iNOS was downregulated (0.3 ±
0 . 1f o l do fw t ,p< 0 . 0 5 )i nm u t a n tS O D 1m i c es p i n a l
cords compared to wt mice. Pegfilgrastim treatment
decreased the expression of TNFa (to 19 ± 11 fold of
wt) but interestingly, increased the expression of iNOS
(to 0.8 ± 0.4 fold of wt), altering the inflammatory status
closer to the wt situation, although these changes did
not reach statistical significance. Since one of the down-
stream effectors of nitric oxide is Nrf2 [52-54], we
further determined the Nrf2 target genes in the spinal
cord. There was upregulation of HO1 and NQO1 in
mutant SOD1 mice compared to wt mice (9.2 ± 1.5 fold
of wt, p <0.001 and 2.9 ± 1.0 fold of wt, p <0.01, respec-
tively) but pegfilgrastim did not affect the expression of
these Nrf2 target genes. The expression of iNOS was
t h u sn o tc o m b i n e dw i t hN r f 2t a r g e tg e n ee x p r e s s i o no f
HO1 and NQO1, but these were regulated indepen-
dently. This also suggests that the protective effects of
pegfilgrastim in mutant SOD1 mice were not mediated
by Nrf2.
GCSF attenuates inflammation in microglia and peripheral
monocytes
Since TNFa was highly upregulated in the spinal cord of
mutant SOD1 mice, we further determined the effect of
GCSF on inflammatory cells in the CNS and peripheral
hematopoietic organs. GCSF decreased inflammation-
induced TNFa release in primary microglia cells in vitro
(4A, p <0.001). GCSF also decreased the TNFa release
in bone marrow (BM) monocytes in vitro obtained from
wt and mutant SOD1 mice (4B, p <0.001). Furthermore,
TNFa release was decreased in BM monocytes obtained
from long-term pegfilgrastim-treated mutant SOD1
mice compared to vehicle-treated littermates (4C, p
<0.05), suggesting a notable relevance in vivo.I na d d i -
tion to the reduction of TNFa production, the NO
release was increased with GCSF in mutant SOD1 BM
monocytes in vitro (4D, p <0.05) and in BM and spleen
monocytes obtained from long-term pegfilgrastim-trea-
ted SOD1 mice (4E and 4F, p <0.001).
GCSF modulates cell populations in peripheral
hematopoietic organs and in degenerating muscle
When measuring spleen size, we discovered decreases in
weight (5A, p <0.01) and length (5B, p <0.001) of end
stage mutant SOD1 mice compared to wt controls at
the same age. In comparison, the body weight of mutant
SOD1 mice at the end stage had dropped to 75 ± 14%
of wt mouse weight. Pegfilgrastim treatment increased
t h es p l e e ns i z eo fm u t a n tS O D 1m i c e( 5 Aa n d5 B ,p
<0.001) in a similar manner to wt mice indicating a
long-term biological efficacy of GCSF on SOD1 mice.
We further analyzed hematopoietic cell populations
after long-term pegfilgrastim treatment from 20-week
old mutant SOD1 mice. GCSF increased the number of
total splenocytes (5C, p <0.001) but not the total num-
ber of BM leukocytes (5D). In BM, the number of lym-
phocytes was either not affected (CD3; 0.5 ± 0.1 million
in control (vehicle-treated) and 0.4 ± 0.1 million in
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control and 1.7 ± 0.3 million in GCSF-treated, p <0.001)
in response to pegfilgrastim treatment. On contrary to
this, the number of Ly6C monocytes was increased (5E,
p <0.01) in BM after pegfilgrastim treatment. Notably,
the number of Ly6C
int cells was increased. Ly6C is a
marker for myeloid lineage of cells and a component of
myeloid differentiation antigen Ly6C/Ly6G, the latter
expressed mainly in polymorphonuclear lineage of mye-
loid cells. Ly6C cells also expressed CD11b, an integrin
involved in adhesive interactions and migration of mye-
loid cells. The number of cells expressing CD115, the
Figure 2 GCSF is neuroprotective in vitro. Primary spinal cord neuronal culture expressed >90% neurons, majority of which were interneurons,
positive for NeuN (A) while a small fraction of cells were motoneurons, positive for SMI-32 (B). When spinal cord neurons were treated with
GCSF for 24 h, the Akt phosphorylation (pAkt) was increased (C). b-actin is shown as a loading control and the data was normalized to b-actin
control in quantification. GCSF increased pAkt as quantified from western blot data (C, p <0.05, n = 3). The molecular weight of pAkt and b-actin
are 60 and 42 kDa, respectively. When spinal cord neurons were exposed to glutamate, GCSF protected the neurons from glutamate
excitotoxicity (D, p <0.001, n = 18-20). GCSF did not have any effect of neuron survival in control conditions (D, n = 14). When spinal cord
neuron culture was prepared from mutant SOD1 mice, we discovered that the general cell viability was slightly reduced in mutant SOD1
neurons (E, p <0.001, n = 16 embryos). GCSF increased the cell viability in mutant SOD1 neurons (E, p <0.05, n = 16 embryos). The scale bar is
50 μm.
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Page 7 of 14Figure 3 GCSF with sustained activity attenuates inflammation in spinal cord in mutant SOD1 mice in vivo. Spinal cord sections were
analyzed after long-term pegfilgrastim treatment from the end stage mutant SOD1 mice. The neuronal survival was decreased in mutant SOD1
mice compared to wt mice (A), determined from the ventral horn of the spinal cord. Long-term pegfilgrastim treatment did not notably rescue
the cells from neurodegeneration in the spinal cord as determined with Map2, NeuN and ChAT immunostaining (3A and 3B, n = 5). However,
when the inflammation status was analyzed from the same mice, long-term pegfilgrastim treatment decreased the inflammation in the spinal
cord as determined with GFAP and Iba-1 immunostaining (A and B, p <0.05 and p <0.01 respectively, n = 5). The quantitation in (B) for Map2,
NeuN, ChAT, GFAP and Iba-1 is shown as immunoreactive area in fold of wt mice spinal cord sections. The scale bar is 50 μm.
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Page 8 of 14receptor for macrophage colony stimulating factor was
however not increased by pegfilgrastim.
In spleen, the number of lymphocytes was elevated
(CD3; 31 ± 1.6 million in control and 44 ± 3.5 million
in GCSF-treated, p <0.01) or remained at the same level
(CD45R; 86 ± 8 million in control and 106 ± 32 million
in GCSF-treated) in response to pegfilgrastim treatment.
Similar to BM, the number of monocytes was increased
(5E, p <0.05) in spleen after long-term pegfilgrastim
treatment. Particularly the number of Ly6
int population
of monocytes which represented low or no pro-
inflammatory cytokine activation in response to an
inflammatory stimulus was elevated (5E, 5F, 5G). These
findings thus indicate that pegfilgrastim increased the
production/storage of Ly6C monocytes in BM and
spleen.
When mononuclear cell population was analyzed from
the thigh muscle including the sciatic nerve at the
symptomatic stage of ALS when there are pronounced
deficits of motoric function, the Ly6C monocyte number
was increased while lymphocyte number was decreased
in response to pegfilgrastim treatment (5H, p <0.05).
Lymphocytes were distinguished from monocytes based
on their side scatter and forward scatter properties and
their expression of lymphocyte or monocyte markers as
defined above. GCSF probably increases the storage of
certain Ly6C monocytes with migratory properties in
spleen and BM. GCSF was also detected to increase the
number of CCR2 expressing cells, which is a marker for
migratory cells, in BM and spleen as analyzed with flow
cytometry (data not shown). In summary, this suggests
the GCSF treatment increased the availability of mono-
cytes in the symptomatic stage of ALS in SOD1 mice.
S i n c et h e s ec e l l sh a v eaf a v o r able inflammatory profile,
they may be recruited to the degenerative muscle as an
attempt for recovery processes.
Discussion
G C S Fh a sp r o v e nt ob eas a f et r e a t m e n ti nA L Si n
phase I studies, administered as a single [36,37] or
repeated cycles with three months interval [38,39].
GCSF mobilizes hematopoietic stem cells from ALS
patients in a consistent manner [55] and GCSF-mobi-
l i z e ds t e mc e l l sc o u l db et r a n s p l a n t e db a c kt oA L S
patients causing no adverse effects [36]. The clinical
trials so far have shown limited improvement in ALS
pathology. The reason for this may be the fact that
GCSF was administered for a short period of time; only
single or repeated cycles of few days of duration were
given. Since long-term usage of GCSF may have severe
side effects such as splenomegaly and even a spleen
rupture, the targeted GCSF delivery may be an option if
the mechanisms of action of GCSF were known in
detail. The intraspinal delivery of GCSF with an adeno-
associated virus (AAV)-GCSF vector was beneficial in
mutant SOD1 mice; the neuromuscular junctions were
preserved and motoneuron survival was increased [56].
Although the local intraspinal or intramuscular delivery
of AAV-GCSF, it still had a systemic effect with
increased levels of GCSF in serum and the induction of
hematopoiesis [56]. Even though GCSF has a moderate
effect on mutant SOD1 mouse survival, as we describe
in this study, the GCSF-mediated effects on the modu-
lation of inflammation are interesting and highly rele-
vant in the light of ALS pathology.
Figure 4 GCSF modulates inflammatory responses in vitro and
ex vivo. Cells were treated in vitro with 10 ng/ml LPS for 24 h and
TNFa release was quantified with ELISA. GCSF decreased the
production of TNFa in primary microglia (A, p <0.001, n = 3). GCSF
also decreased the TNFa production in BM monocytes obtained
from wt and mutant SOD1 mice (B, p <0.001, n = 6-7). TNFa
production was also decreased in BM Ly6C monocytes isolated from
20 week-old, long-term pegfilgrastim-treated mutant SOD1 mice, as
compared to their vehicle-treated littermates (C, p <0.001, n = 3):
TNFa production was analyzed with intracellular cytokine staining
with flow cytometry after 4 h incubation of 1 μg/ml LPS ex vivo.N O
production was detected with determination of NO metabolites
NO2 and NO3 from the medium after 24 h of incubation with 10
ng/ml LPS. NO production was increased after LPS stimulation in wt
(D, p <0.001, n = 4-8) and mutant SOD1 BM monocytes in vitro (D,
p <0.05, n = 7-8). GCSF further increased the NO production in
mutant SOD1 monocytes up to the level of wt monocytes (D, p
<0.05, n = 7-8). NO production was also increased in BM (E, p
<0.001, n = 3) and spleen (F, p <0.001, n = 3) leukocytes obtained
from long-term pegfilgrastim-treated mutant SOD1 mice, as
compared to their vehicle-treated littermates: NO production was
analyzed after 24 h of incubation with 100 ng/ml LPS.
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Page 9 of 14Figure 5 GCSF with sustained action increases the availability of monocytes in hematopoietic organs and monocyte recruitment into
the degenerating muscle. Spleen size was decreased at late stage mutant SOD1 mice as assessed by weight (A, p <0.01, n = 6-11) and length
(B, p <0.001, n = 6-11) as compared to wt control mice at the same age. Pegfilgrastim treatment increased the spleen size of mutant SOD1 mice
(A, B, p <0.001, n = 6-11). The dotted line represents the spleen size of wt mice after long-term pegfilgrastim treatment (A, B). Long-term
pegfilgrastim treatment also increased the number of splenocytes (C, p <0.001, n = 3) as analyzed from 20-week old mutant SOD1 mice. The
number of leukocytes in BM was determined from the same mice (D): pegfilgrastim did not affect the total leukocyte number in BM but altered
the composition of BM cell populations increasing the number of monocytes (E, p <0.01, n = 3). The similar effect on cell composition was
detected is spleen cell populations (F, p <0.05, n = 3). The monocyte population which number was greatly increased, namely Ly6C
int had low
or no production of cytokine after LPS stimulus (G, middle), in comparison to Ly6C
hi monocytes which represented high cytokine production for
inflammatory stimulus (G, below) as analyzed by flow cytometry. When mononuclear cell population was analyzed from the thigh muscle
including the sciatic nerve in mutant SOD1 mice at symptomatic stage, the Ly6C monocytosis was increased while lymphocytosis was decreased
(H, p <0.05, n = 3).
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Page 10 of 14In animal studies, long-term GCSF (filgrastim) admin-
istration with a subcutaneously implanted osmotic mini-
pump, has been shown to increase the survival of
mutant SOD1 mice accompanied with increased moto-
neuron survival and induction of an anti-apoptotic path-
way in neurons [28]. Also, the GCSF expression
restricted to CNS enhanced mutant SOD1 mouse survi-
val. The mechanism of GCSF effect was suggested as a
direct protection of motoneurons. The increase in the
motoneuron survival was detected when analyzed at 15
weeks of age, i.e. at the time of clinical onset and no
effect on astro-or microgliosis was detected when ana-
lyzed at 19 weeks of age. Using the same mutant SOD1
strain in our studies we detected an increase in the sur-
vival of mutant SOD1 mice after long-term administra-
tion of GCSF with weekly injections of pegfilgrastim.
This pegylated filgrastim has a sustained effect due to
the reduced renal clearance. We suggest pegfilgrastim to
slow the progression of the disease since the treatment
did not affect the onset of the disease. However, it is
rather unlikely that pegfilgrastim treatment started at
the age of 12 weeks could still postpone the onset of
motor deficits since subclinical pathological features of
ALS have already progressed at the time of clinical
o n s e ta ta r o u n d1 7w e e k sw h e nf i r s tm o t o rd e f i c i t sc a n
be detected in SOD1 mouse. When analyzed at the end
stage of ALS, we did not detect neuroprotection in
spinal cord of mutant SOD1 mice to same extent as
detected in younger, symptomatic SOD1 mice [28].
However, we detected an evident reduction in astro-
and microgliosis in the spinal cord of pegfilgrastim trea-
ted mutant SOD1 mice, as analyzed with GFAP and
Iba-1 immunostaining reacting with astrocytes and all
monocytic cells in the spinal cord, respectively. When
studied with primary spinal cord neurons in vitro,w e
detected a GCSF-mediated neuroprotection with a simi-
lar activation of the P13K/Akt anti-apoptotic pathway as
described earlier [28]. However, our results suggest that
the anti-inflammatory effect of GCSF plays an important
role in the progression of ALS. Although GCSF was not
able to significantly reduce the decline of neuronal den-
sity in the spinal cord when analyzed with immunohis-
tochemistry at the end stage, it preserved the neuronal
innervation in the periphery by preventing the presynap-
tic decline of neuromuscular transmission (Naumenko
and Pollari et al., unpublished). This suggests that the
reduction of inflammation by GCSF demonstrated in
this study in vitro and in vivo is indeed accompanied
with enhanced neuronal function.
Boillée et al. demonstrated that the mutant SOD1
expression in motoneurons is a determinant of the ALS
onset while the expression of mutant SOD1 in macro-
phages/microglia participated in ALS progression in
later stage [57]. In addition, the expression of mutant
SOD1 only in motoneurons or astrocytes was not suffi-
cient for ALS pathology [58,59]. However, mutant
SOD1 expression in astrocytes caused a release of solu-
ble factors toxic to motoneurons [60]. This suggests that
myeloid cells/microglia and astrocytes, as inflammation
participating cells have high input to ALS progression.
In our study, the TNFa expression was increased over
30-fold in the spinal cord of mutant SOD1 mice com-
pared to wt mice. This was accompanied by a pro-
nounced astro- and microgliosis indicating
inflammation. When we analyzed the inflammatory
properties of mononuclear phagocytes, i.e. microglia and
peripheral monocytes, we discovered that exogenously
applied GCSF in vitro or pegfilgrastim treatment in vivo,
respectively, reduces the capacity of TNFa production.
Since the reduced production of TNFa was accompa-
nied with increased but modest production of NO at
the same cells, we suggest NO to conduct an advanta-
geous signaling within this context. Although NO is
generally linked to proinflammatory signaling, it may
exert protective effect in attempt to combat for oxida-
tive stress or increase anti-apoptotic signaling [61-64].
The long-term treatment with NOS inhibitor did not
have a protection in mutant SOD1 mice which argues
for the role of NO solely as a proinflammatory mediator
in ALS [65]. NO was recently shown to be involved in
GCSF-mediated regeneration in chronic myocardial dis-
ease [66].
When analyzed from the hematopoietic organs, pegfil-
grastim treatment increased the number of monocytes
with modest TNFa production capacity. These cells,
which expressed Ly6C, are stored in hematopoietic
organs and may be recruited into the degenerative tis-
sue. Ly6C is expressed in migratory monocytes which
may shuttle between the circulation and the BM and
enter the inflammatory tissue to become dendritic cells
or macrophages [67-71], which participate in inflamma-
tory and healing processes. Recently, it was shown that
in addition to BM, the spleen also works as storage for
Ly6C monocytes which are released and transmigrated
into the heart after myocardial infarction [70]. We
detected pegfilgrastim treatment to increase the avail-
ability of Ly6C monocytes in both BM and spleen. We
also found that pegfilgrastim increased the proportion of
monocytes out of other leukocytes in the muscle in
mutant SOD1 mice when analyzed at symptomatic
stage. This finding suggests that the increased availabil-
ity of monocytes in the hematopoietic organs may also
increase the availability of regenerative monocytes in the
damaged tissue.
Furthermore, since BM cells have been shown to
migrate into the spinal cord of mutant SOD1 mice
[10-13] and peripheral nerves/muscles [10,14], the
increased availability of the migratory subpopulation of
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Page 11 of 14monocytes which have reduced proinflammatory activa-
tion may decrease the inflammation and neurotoxicity
and on the other hand, enhance the regeneration pro-
cesses [72,73]. As recently demonstrated, the mutant
SOD1 mice accumulated macrophages from the early
stage of ALS throughout the disease progression [14,74];
the spinal cord microglia were endogenously-derived
while in the PNS the majority of macrophages were ori-
ginated from the circulation. This further emphasizes
the importance of GCSF effect on the increased avail-
ability of migratory monocytes with reduced proinflam-
matory action.
The induction of motoneuron death and neurodegen-
eration in ALS has been described as a “dying forward”
manner where the motoneuronal pathology starts from
at the soma [75], or as a “dying back” manner where the
motoneuronal pathology starts at the distal axons and
proceeds back to the motoneuron soma [6]. Since GCSF
exerts its inflammation-modulating effects in the CNS
and the periphery, it may hinder the disease progression
at multiple sites. In our study, GCSF strongly modulated
the composition of inflammatory cell populations, their
availability and potentially also their migration into
degenerative muscle in a mouse model of ALS. It
remains to be further investigated whether i) the trans-
plantation of BM or spleen cells obtained from GCSF-
mobilized mouse or ii) the transplantation of ex vivo
GCSF-treated monocytes is sufficient to achieve the
GCSF-mediated protection in a mouse model of ALS
and which monocyte subpopulations in particular are
involved in these processes.
Conclusions
The present data demonstrate that GCSF attenuates
inflammation in a mouse model of ALS which slows
down the progression of the disease. GCSF reduced
inflammation in the CNS and the periphery while
increasing the availability of anti-inflammatory migratory
monocytes. This mechanism of action targeting neuroin-
flammation and peripheral inflammation-participative
cells provides a new perspective of the usage of GCSF in
the treatment of ALS.
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